Home/Pipeline/DMD Gene Therapy

DMD Gene Therapy

Duchenne Muscular Dystrophy

Pre-clinicalActive

Key Facts

Indication

Duchenne Muscular Dystrophy

Phase

Pre-clinical

Status

Active

Company

Kinea Bio

About Kinea Bio

Kinea Bio is a private, pre-clinical-stage biotech developing innovative gene therapy platforms and programs for neuromuscular diseases (NMDs) with high unmet need. The company has built a multi-faceted technology suite, including SIMPLI-GT™ for large gene delivery, MyoXpress™ for tuned muscle expression, myotropic capsids for targeted delivery, and BioDrone™ for non-immunogenic repeat administration. Backed by respected scientific founders, non-dilutive NIH grants, and foundation investments, Kinea is advancing a pipeline led by programs for Duchenne Muscular Dystrophy (DMD) and dysferlinopathy.

View full company profile

Therapeutic Areas

Neuromuscular Diseases

Other Duchenne Muscular Dystrophy Drugs

Drug	Company	Phase	Status
MyoPAXon	Myogenica	Phase 1	Active
NS-051/NCNP-04	NS Pharma	Phase 1/2	Active
UCT-MSC + Biomaterials	Vitti Labs	Phase 2	Active
Myosana Platform for DMD	Myosana Therapeutics	Pre-clinical	Active
PEPR-124 (RT-001)	Peptris Technologies Private	Phase 2-ready	Licensed to Revio Therapeutics
DMD Genetic Screening Panel	Nanodigmbio	Commercial	Active
KHR‑001	KAHR Medical	Preclinical	Active
PF-06939926	Pfizer	Phase 3	Active